Register Login

Milestone Pharmaceuticals Inc (MIST)

(80% Positive) MILESTONE PHARMACEUTICALS INC. (MIST) Announces Enrollment Update for etripamil Due to Pandemic-Related Challenges, Patient Enrollment Issues, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 6, 2026, 1:11 p.m.

    📋 MILESTONE PHARMACEUTICALS INC. (MIST) - Clinical Trial Update

    Filing Date: 2026-01-06

    Accepted: 2026-01-06 08:05:44

    Event Type: Clinical Trial Update

    Event Details:

    Milestone Pharmaceuticals Inc (MIST) Announces Clinical Trial Update Milestone Pharmaceuticals Inc (MIST) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: etripamil
    • Collaboration: a Marketing Authorization Application
    • Updated Timeline: Q1 2027
      • expected by Q1 2027
      • expected by the first quarter of 2027

    🔬 Clinical Development Pipeline (MILESTONE PHARMACEUTICALS INC.):

    Product Type Development Stage Therapeutic Area Source
    Nofazinlimab (CS1003) Placebo+Lenvatinib DRUG Phase PHASE3 Hepatocellular Carcinoma ClinicalTrials.gov
    Nofazinlimab (CS1003)+Lenvatinib DRUG Phase PHASE3 Hepatocellular Carcinoma ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Milestone Pharmaceuticals Inc
    • CIK: 0001408443
    • Ticker Symbol: MIST
    • Period End Date: 2026-01-06
    • Document Type: 8-K

Search

News categories